Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Journal Information
Full Title: Ann Rheum Dis
Abbreviation: Ann Rheum Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests: The ARTIS project is supported by agreements between Karolinska Institutet (with JA as PI) and the listed entities, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS): Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi. TF, HB, DDG and BD are partly employed by the ARTIS project. EL, MM, NF, UL and HFdE report no conflict of interest."
"Funding: TF was supported by the Swedish Research Council (2016-00398, 2021-01418). JA was supported by the Swedish Research Council, Region Stockholm/Karolinska Institutet (ALF), the Swedish HeartLung-Foundation, the Swedish Cancer Society, Nordforsk and Vinnova."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025